{
    "2018-09-27": [
        [
            {
                "time": "2018-11-20",
                "original_text": "IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "Class Action",
                        "AbbVie Inc.",
                        "Investor Alert"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018",
                "features": {
                    "keywords": [
                        "Class Action",
                        "AbbVie Inc.",
                        "Shareholder Alert"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV",
                "features": {
                    "keywords": [
                        "Class Action",
                        "AbbVie Inc.",
                        "Securities"
                    ],
                    "sentiment_score": -0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-10-31",
                "original_text": "Pfizerâ€™s Earnings Quality and Dividend Performance",
                "features": {
                    "keywords": [
                        "Earnings Quality",
                        "Dividend Performance",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "Peek Under The Hood: EQWL Has 10% Upside",
                "features": {
                    "keywords": [
                        "Upside",
                        "EQWL"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-25",
                "original_text": "Gilead Sciences' Latest Tactic? Go Generic",
                "features": {
                    "keywords": [
                        "Gilead Sciences",
                        "Generic",
                        "Tactic"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}